TY - JOUR
TI - Balloon Pulmonary Angioplasty in Patients with Chronic Thromboembolic Pulmonary Hypertension in Greece: Data from the Hellenic Pulmonary Hypertension Registry
AU - Karyofyllis, P.
AU - Demerouti, E.
AU - Giannakoulas, G.
AU - Anthi, A.
AU - Arvanitaki, A.
AU - Athanassopoulos, G.
AU - Feloukidis, C.
AU - Iakovou, I.
AU - Kostelidou, T.
AU - Mitrouska, I.
AU - Mouratoglou, S.-A.
AU - Orfanos, S.E.
AU - Pappas, C.
AU - Pitsiou, G.
AU - Tsetika, E.-G.
AU - Tsiapras, D.
AU - Voudris, V.
AU - Manginas, A.
JO - Journal of Clinical Medicine Research
PY - 2022
VL - 11
TODO - 8
SP - null
PB - MDPI
SN - 1918-3003, 1918-3011
TODO - 10.3390/jcm11082211
TODO - null
TODO - Balloon pulmonary angioplasty (BPA) is a novel and promising treatment option for patients with chronic thromboembolic pulmonary hypertension (CTEPH) who are ineligible for pulmonary endarterectomy (PEA) and for those with persistent or recurrent pulmonary hypertension after PEA. We present the results of BPA procedures in CTEPH patients included in the Greek Pulmonary Hypertension Registry, evaluating the real-life efficacy and safety. We analyzed data from 180 BPA procedures (2–17/patient, mean 8 ± 4/patient, 1248 dilated vessels, 0–18/session). Significant improvements were observed in mean pulmonary arterial pressure (a reduction by 44%, p < 0.001), pulmonary vascular resistance (reduction by 60%, p < 0.001), and NT-proBNP (decrease by >70%, p: 0.003), while cardiac index improved modestly (9% increase, p = 0.143). We had 37 BPA-related non-fatal complications (20.6% in all interventions), predominantly including hemoptysis. Overall survival was 91%, 75% and 62% at 3, 4 and 5 years, respectively. Therefore, BPA may be a promising therapeutic option in patients with CTEPH in Greece. © 2022 by the authors. Licensee MDPI, Basel, Switzerland.
ER -